Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 28 September
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis 24 September
European Commission Approves DAYBU® as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union 24 August
